| Literature DB >> 30381783 |
Richard Southworth1, Rafael Torres Martin de Rosales1, Levente K Meszaros1, Michelle T Ma1, Gregory E D Mullen1, Gilbert Fruhwirth1, Jennifer D Young1, Cinzia Imberti1, Julia Bagunya-Torres1, Erica Andreozzi1, Philip J Blower1.
Abstract
The development of medical imaging is a highly multidisciplinary endeavor requiring the close cooperation of clinicians, physicists, engineers, biologists and chemists to identify capabilities, conceive challenges and solutions and apply them in the clinic. The chemistry described in this article illustrates how synergistic advances in these areas drive the technology and its applications forward, with each discipline producing innovations that in turn drive innovations in the others. The main thread running through the article is the shift from single photon radionuclide imaging towards PET, and in turn the emerging shift from PET/CT towards PET/MRI and further, combination of these with optical imaging. Chemistry to support these transitions is exemplified by building on a summary of the status quo, and recent developments, in technetium-99m chemistry for SPECT imaging, followed by a report of recent developments to support clinical application of short lived (Ga-68) and long-lived (Zr-89) positron emitting isotopes, copper isotopes for PET imaging, and combined modality imaging agents based on radiolabelled iron oxide based nanoparticles.Entities:
Keywords: contrast agents; copper; gallium; positron emission tomography; radiopharmaceuticals; technetium; zirconium
Year: 2015 PMID: 30381783 PMCID: PMC6205628 DOI: 10.1016/bs.adioch.2015.09.001
Source DB: PubMed Journal: Adv Inorg Chem ISSN: 0898-8838 Impact factor: 3.282